Pancreatic Cancer Research

ResearcherUniversity of DebrecenActive in the last 2 years

Alexandr V. Bazhin

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7581-4533; OpenAlex author ID A5102883702. Sources: OpenAlex.

Their work

Papers
24 (first author 0, last author 7)
Trials
0
Grants
0
Labs led
1
Collaborators
71
Papers, trials and grants by year

2013: 1 paper · 2014: 4 papers · 2015: 4 papers · 2016: 1 paper · 2017: 1 paper · 2018: 3 papers · 2019: 2 papers · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: 3 papers · 2024: 1 paper · 2025: 1 paper

Papers 24

  1. Prognostic value of tumor-infiltrating lymphocytes, tumor associated neutrophils and metabolic checkpoint molecules on survival of patients with metastatic pan… Co-author DOI 10.1016/j.sipas.2025.100320↗
  2. Correction: Aspirin counteracts cancer stem cell features, desmoplasia and gemcitabine resistance in pancreatic cancer. Co-author DOI 10.18632/oncotarget.28527↗
  3. SPOCK2 gene expression is downregulated in pancreatic ductal adenocarcinoma cells and correlates with prognosis of patients with pancreatic cancer. Last author DOI 10.1007/s00432-023-04845-5↗
  4. In-vitro model to mimic T cell subset change in human PDAC organoid co-culture. Co-author DOI 10.1007/s00432-023-05100-7↗
  5. WNT enhancing signals in pancreatic cancer are transmitted by LGR6. Co-author DOI 10.18632/aging.205101↗
  6. Pivotal antitumor role of the immune checkpoint molecule B7-H1 in pancreatic cancer. Co-author DOI 10.1080/2162402x.2022.2043037↗
  7. Identification of the Neurokinin-1 Receptor as Targetable Stratification Factor for Drug Repurposing in Pancreatic Cancer. Co-author DOI 10.3390/cancers13112703↗
  8. The Role of Stellate Cells in Pancreatic Ductal Adenocarcinoma: Targeting Perspectives. Co-author DOI 10.3389/fonc.2020.621937↗
  9. The role of interleukin-18 in pancreatitis and pancreatic cancer. Co-author DOI 10.1016/j.cytogfr.2019.11.001↗
  10. Prognostic Impact of Tumor-Infiltrating Lymphocytes and Neutrophils on Survival of Patients with Upfront Resection of Pancreatic Cancer. Co-author DOI 10.3390/cancers11010039↗
  11. Therapies Targeting the Tumor Stroma and the VEGF/VEGFR Axis in Pancreatic Ductal Adenocarcinoma: a Systematic Review and Meta-Analysis. Co-author DOI 10.1007/s11523-018-0578-x↗
  12. Immune Cell and Stromal Signature Associated With Progression-Free Survival of Patients With Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1053/j.gastro.2018.08.009↗
  13. Notch-Induced Myeloid Reprogramming in Spontaneous Pancreatic Ductal Adenocarcinoma by Dual Genetic Targeting. Co-author DOI 10.1158/0008-5472.can-18-0052↗
  14. MiRNAs are Unlikely to be Involved in Retinoid Receptor Gene Regulation in Pancreatic Cancer Cells. Last author DOI 10.1159/000485276↗
  15. Relationship Between All-trans-13,14-Dihydro Retinoic Acid and Pancreatic Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000000601↗
  16. Reduced retinoids and retinoid receptors' expression in pancreatic cancer: A link to patient survival. Last author DOI 10.1002/mc.22158↗
  17. Anti-tumor properties of the cGMP/protein kinase G inhibitor DT3 in pancreatic adenocarcinoma. Last author DOI 10.1007/s00210-015-1147-9↗
  18. Prognostic and predictive value of immunological parameters for chemoradioimmunotherapy in patients with pancreatic adenocarcinoma. Last author DOI 10.1038/bjc.2015.72↗
  19. Aspirin counteracts cancer stem cell features, desmoplasia and gemcitabine resistance in pancreatic cancer. Co-author DOI 10.18632/oncotarget.3171↗
  20. Two immune faces of pancreatic adenocarcinoma: possible implication for immunotherapy. Co-author DOI 10.1007/s00262-013-1485-8↗
  21. Interlude of cGMP and cGMP/protein kinase G type 1 in pancreatic adenocarcinoma cells. Last author DOI 10.1097/mpa.0000000000000104↗
  22. Inhibition of glucose turnover by 3-bromopyruvate counteracts pancreatic cancer stem cell features and sensitizes cells to gemcitabine. Co-author DOI 10.18632/oncotarget.2120↗
  23. Influence of interferon-alpha combined with chemo (radio) therapy on immunological parameters in pancreatic adenocarcinoma. Last author DOI 10.3390/ijms15034104↗
  24. Overcoming immunosuppression as a new immunotherapeutic approach against pancreatic cancer. Co-author DOI 10.4161/onci.25736↗

Closest collaborators

The 25 strongest of 71 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jens Werner · 16 shared papers, 2013–2025 · strength 1.61
  2. Jan Goesta D’Haese · 9 shared papers, 2015–2025 · strength 1.09
  3. Bernhard Willibald Renz · 4 shared papers, 2021–2025 · strength 0.66
  4. Matthias Ilmer · 4 shared papers, 2021–2025 · strength 0.66
  5. Maximilian Weniger · 4 shared papers, 2018–2025 · strength 0.61
  6. Svetlana Karakhanova · 8 shared papers, 2013–2022 · strength 0.52
  7. Ughur Aghamaliyev · 2 shared papers, 2023–2025 · strength 0.43
  8. Hanno Nieß · 3 shared papers, 2021–2023 · strength 0.43
  9. Iris Beirith · 3 shared papers, 2021–2023 · strength 0.43
  10. Steffen Ormanns · 3 shared papers, 2018–2025 · strength 0.38
  11. Rainer Christoph Miksch · 2 shared papers, 2019–2025 · strength 0.33
  12. Eduard Ryschich · 3 shared papers, 2015–2024 · strength 0.28
  13. Orkhan Isayev · 3 shared papers, 2014–2022 · strength 0.27
  14. Jens Martin Werner · 3 shared papers, 2015–2020 · strength 0.27
  15. Nathalie Bauer · 3 shared papers, 2014–2024 · strength 0.26
  16. Pei Fan · 3 shared papers, 2014–2024 · strength 0.26
  17. Yiyao Zhang · 3 shared papers, 2014–2024 · strength 0.26
  18. Ingrid Herr · 3 shared papers, 2014–2024 · strength 0.26
  19. Tao Zhang · 1 shared paper, 2025 · strength 0.23
  20. Nathalia A. Giese · 2 shared papers, 2015–2024 · strength 0.23
  21. Franco Fortunato · 2 shared papers, 2015–2024 · strength 0.23
  22. Thilo Hackert · 2 shared papers, 2015–2024 · strength 0.23
  23. Li Liu · 2 shared papers, 2015–2024 · strength 0.23
  24. Oliver Strobel · 2 shared papers, 2015–2024 · strength 0.23
  25. Jens Thomas Siveke · 2 shared papers, 2018–2022 · strength 0.23

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.